1. Home
  2. BKKT vs TTRX Comparison

BKKT vs TTRX Comparison

Compare BKKT & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bakkt Holdings Inc.

BKKT

Bakkt Holdings Inc.

HOLD

Current Price

$7.45

Market Cap

350.1M

Sector

Technology

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$8.75

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BKKT
TTRX
Founded
2018
2015
Country
United States
United States
Employees
48
2
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
350.1M
281.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BKKT
TTRX
Price
$7.45
$8.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$21.50
$8.00
AVG Volume (30 Days)
1.1M
124.9K
Earning Date
05-12-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$261.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.87
$2.57
52 Week High
$49.79
$11.69

Technical Indicators

Market Signals
Indicator
BKKT
TTRX
Relative Strength Index (RSI) 41.11 55.17
Support Level $7.11 $8.51
Resistance Level $9.66 $11.69
Average True Range (ATR) 0.49 1.12
MACD -0.02 -0.10
Stochastic Oscillator 22.70 27.11

Price Performance

Historical Comparison
BKKT
TTRX

About BKKT Bakkt Holdings Inc.

Bakkt Inc builds digital financial infrastructure designed to support institutional participation in the digital asset economy. The company platform is built to accommodate various digital assets and offers its clients the flexibility to build a product that aligns with its vision and customers' needs. Its services include Bakkt Markets, Bakkt Agent, Bakkt Global.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: